Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.
Paul EmerySarah HortonRaluca Bianca DumitruKamran NaraghiDésirée Mfm van der HeijdeRichard J WakefieldElizabeth M A HensorMaya H BuchPublished in: Annals of the rheumatic diseases (2020)
Compared with remission rates typically reported with first-line tumour necrosis factor inhabitor+MTX versus MTX-TT, we did not demonstrate a larger effect in very ERA. Neither strategy conferred remission in the majority of patients although ultrasound confirmed local inflammation suppression. Poorer ETN response following failure of MTX-TT is also suggested. Trial registration number NCT02433184.
Keyphrases
- study protocol
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- rheumatoid arthritis patients
- end stage renal disease
- clinical trial
- ejection fraction
- randomized controlled trial
- juvenile idiopathic arthritis
- newly diagnosed
- oxidative stress
- chronic kidney disease
- phase ii
- prognostic factors
- ulcerative colitis
- patient reported outcomes
- computed tomography
- systemic sclerosis
- idiopathic pulmonary fibrosis